Claims
- 1. A method for monitoring human H37 gene products comprising:
determining the status of H37 gene products expressed by cells in a tissue sample from an individual; comparing the status so determined to the status of H37 gene products in a corresponding normal sample; and identifying an alteration in H37 gene products in the tissue sample relative to the normal sample.
- 2. A method of monitoring the presence of cancer in an individual comprising: performing the method of claim 1 wherein decreased H37 mRNA or protein expression in the test sample relative to the normal tissue sample provides an indication of the presence or status of a cancer.
- 3. The method of claim 2, wherein the cancer occurs in breast, ovarian or lung tissue.
- 4. The method of claim 1, wherein the H37 gene products are polynucleotides.
- 5. The method of claim 1, wherein the H37 gene products are polypeptides.
- 6. A method for evaluating a neoplasm in a patient comprising examining the quantity of functional H37 gene products in cells from neoplastic tissue of the patient, and comparing the quantity of functional H37 gene products in neoplastic cells to the quantity of functional H37 gene products in non-neoplastic cells of the patient, wherein a reduced quantity of functional H37 gene products in the neoplastic cells is indicative of growth disregulation.
- 7. The method of claim 6, wherein the status of the H37 gene is determined by a protocol selected from the group consisting of Southern hybridization, Northern hybridization, Western blotting, polymerase chain reaction and polynucleotide sequencing.
- 8. The method of claim 6, wherein the H37 gene products are polynucleotides.
- 9. The method of claim 6, wherein the H37 gene products are polypeptides.
- 10. A method of examining a test biological sample comprising a human breast, ovarian or lung cell for evidence of altered cell growth, the method comprising evaluating the levels of H37 polynucleotides in the biological sample, wherein a decrease in the levels of H37 polynucleotides in the test sample relative to a normal tissue sample provide evidence of altered cell growth; and wherein the levels of H37 polynucleotides in the cell are evaluated by contacting the sample with a polynucleotide probe that specifically hybridizes to a H37 nucleotide sequence shown in SEQ ID NO: 1 and evaluating the presence of a hybridization complex formed by the hybridization of the polynucleotide probe with H37 polynucleotides in the sample.
- 11. The method of claim 10, wherein the presence of a hybridization complex is evaluated by Northern analysis.
- 12. The method of claim 10, wherein the presence of a hybridization complex is evaluated by polymerase chain reaction.
- 13. The method of claim 10, farther comprising evaluating the test biological sample for the presence of an additional factor that is associated with altered cell growth.
- 14. The method of claim 10, wherein the H37 polynucleotides in the test sample are mRNA.
- 15. The method of claim 10, wherein a decrease in the levels of H37 polynucleotides in the test sample relative to a normal tissue sample provide evidence of lung cancer.
- 16. A method of examining a test biological sample comprising a human breast, ovarian or lung cell for evidence of altered cell growth, the method comprising evaluating the levels of H37 polypeptides in the biological sample, wherein a decrease in the levels of H37 polypeptides in the test sample relative to a normal tissue sample provide evidence of altered cell growth; and wherein the levels of H37 polypeptides in the cell are evaluated by contacting the sample with an antibody that immunospecifically binds to a H37 polypeptide sequence shown in SEQ ID NO: 2 and evaluating the presence of a complex formed by the binding of the antibody with H37 polypeptides in the sample.
- 17. The method of claim 16, wherein the presence of a complex is evaluated by a method selected from the group consisting of ELISA analysis, Western analysis and immunohistochemistry.
- 18. The method of claim 16, wherein a decrease in the levels of H37 polypeptides in the test sample relative to a normal tissue sample provide evidence of cancer
- 19. The method of claim 18, wherein a decrease in the levels of H37 polypeptides in the test sample relative to a normal tissue sample provide evidence of lung cancer.
- 20. The method of claim 16, further comprising evaluating the test biological sample for the presence of an additional factor that is associated with altered cell growth.
- 21. A composition comprising an isolated H37 polynucleotide that encodes the amino acid sequence shown in SEQ ID NO: 2.
- 22. A pharmaceutical composition comprising an effective amount of H37 polynucleotide of claim 21 in admixture with a pharmaceutically acceptable carrier.
- 23. A composition comprising an antisense H37 polynucleotide which hybridizes to H37 mRNA in a mammalian cell such that the growth of the cell is modulated, wherein the polynucleotide hybridizes to a complement of the H37 polynucleotide shown in SEQ ID NO: 1 under stringent conditions.
- 24. A composition comprising an isolated H37 polypeptide having the amino acid sequence shown in SEQ ID NO: 2.
- 25. A pharmaceutical composition comprising an effective amount of H37 polypeptide of claim 24 in admixture with a pharmaceutically acceptable carrier.
- 26. A kit comprising:
a container, a label on said container, and a composition contained within said container; wherein the composition includes a polynucleotide that hybridizes to a complement of the H37 polynucleotide shown in SEQ ID NO: 1 under stringent conditions, the label on said container indicates that the composition can be used to evaluate the presence of H37 in at least one type of mammalian cell, and instructions for using the H37 polynucleotide for evaluating the presence of H37 RNA or DNA in at least one type of mammalian cell.
- 27. A method of inhibiting proliferation of a human cell selected from the group consisting of a breast cancer cell, an ovarian cancer cell and a lung cancer cell comprising introducing into the cell an expression vector which comprises a polynucleotide that encodes a polypeptide having an amino acid sequence as shown in SEQ ID NO: 2; wherein following the introduction, the polypeptide is expressed in the cell so that proliferation of the cell is inhibited.
Parent Case Info
[0001] This application is a continuation-in-part of U.S. patent application Ser. No. 09/553,242 filed Apr. 19, 2000, the entire contents of which are incorporated herein by reference.
Government Interests
[0002] This invention was made in part with United States government support under Grant No. DAMD17-94J4234, awarded by the Department of Defense, and Grant No. CA32737, awarded by National Institutes of Health. The Government has certain rights in the invention.
Continuation in Parts (1)
|
Number |
Date |
Country |
Parent |
09553242 |
Apr 2000 |
US |
Child |
09957763 |
Sep 2001 |
US |